TABLE 2.

Hepatic adverse events during the use of immune checkpoint inhibitors (ICIs) according to cancer types

	Any hepatic adverse events during ICIs
All cancer (N = 1480)
Grade 1‐2	611 (41.3)
Grade 3‐4	220 (14.9)
Lung cancer (N = 586)
Grade 1‐2	208 (35.5)
Grade 3‐4	29 (4.9)
Gastrointestinal cancer (N = 148)
Grade 1‐2	74 (50.0)
Grade 3‐4	30 (20.3)
Liver cancer (N = 244)
Grade 1‐2	132 (54.1)
Grade 3‐4	80 (32.8)
Hematological cancer (N = 143)
Grade 1‐2	73 (51.0)
Grade 3‐4	32 (24.4)
Other cancer (N = 359) a
Grade 1‐2	124 (34.5)
Grade 3‐4	49 (13.6)

All results are presented as n (%) of that cancer type. Hepatic adverse events referred to the worst grade of adverse events occurred during follow‐up. Grade 1 hepatic events referred to ALT and/or AST > 1xULN‐3xULN if baseline was normal; 1.5‐3x baseline if baseline was abnormal, and/or total bilirubin > 1xULN‐1.5xULN if baseline was normal; >1‐1.5x baseline if baseline was abnormal. Grade 2 hepatic events referred to ALT and/or AST > 3xULN‐5xULN if baseline was normal; >3‐5x baseline if baseline was abnormal, and/or total bilirubin > 1.5xULN‐3xULN if baseline was normal; >1.5‐3x baseline if baseline was abnormal. Grade 3 hepatic events referred to ALT and/or AST > 5xULN‐20xULN if baseline was normal; >5‐20x baseline if baseline was abnormal, and/or total bilirubin > 3xULN‐10xULN if baseline was normal; >3‐10x baseline if baseline was abnormal. Grade 4 hepatic events referred to ALT and/or AST > 20xULN if baseline was normal; >20x baseline if baseline was abnormal, and/or total bilirubin > 10xULN if baseline was normal; >10x baseline if baseline was abnormal. During ICIs: this refers to the period from the start of ICIs until 4 weeks after the last dose of ICIs.

Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; ICIs, immune checkpoint inhibitors; ULN, upper limit of normal.

^aThe four commonest types of other cancer included kidney cancer, breast cancer, skin cancer, and pharyngeal cancer.